In this sample, the carriers of such variants had a median AAO of 64 years, 8 years earlier than carriers of wild-type SORL1. In comparison, carrying a PTV associated with an overall 17-fold increased risk of overall AD relative to non-carriers, and a 35-fold increased risk of EOAD. This evidence concerns the gene SORL1 and Alzheimer disease.